Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 1.00 |
| ▸ | GSK3A | P49840 | 6/20 | 1.00 |
| ▸ | CDK1 | P06493 | 2/20 | 0.64 |
| ▸ | CDK2 | P24941 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461843 | 0.82 | GSK3B (1.00) | GSK3BGSK3ACDK1CDK2CYP1A2 | |
| SCHEMBL5404007 | 0.81 | GSK3A (1.00) | GSK3BGSK3ACDK1CDK2CCNB2 | |
| SCHEMBL4493121 | 0.80 | GSK3B (1.00) | GSK3BGSK3ACYP1A2 | |
| SCHEMBL31060453 | 0.80 | GSK3B (1.00) | GSK3BGSK3ACYP1A2 | |
| SCHEMBL5390676 | 0.79 | GSK3B (0.69) | GSK3BGSK3ACDK1CDK2 | |
| SCHEMBL1461347 | 0.78 | GSK3B (1.00) | GSK3BGSK3ACDK1CDK2CYP1A2 | |
| Cadaverine Tartrate SCHEMBL5827009 | 0.77 | GSK3A (0.65) | GSK3BGSK3ACDK1CDK2 | |
| SCHEMBL6477490 | 0.77 | GSK3B (1.00) | GSK3BGSK3ACDK1CDK2CYP1A2 | |
| SCHEMBL628628 | 0.77 | GSK3B (0.70) | GSK3BGSK3ACDK1CDK2 | |
| SCHEMBL7155632 | 0.74 | GSK3B (0.62) | GSK3BGSK3ACDK1CDK2CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105532-B2 | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040077681-A1 | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1347972-A1 | PYRAZOLO 3,4-C]PYRIDINES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002050073-A1 | PYRAZOLO[3,4-C]PYRIDINES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077681-A1 | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885CDK1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.